Sana Biotechnology Inc.

AI Score

XX

Unlock

2.29
-0.48 (-17.33%)
At close: Mar 18, 2025, 3:59 PM
2.30
0.00%
Pre-market: Mar 19, 2025, 06:14 AM EDT
-17.33%
Bid 2.25
Market Cap 512.4M
Revenue (ttm) n/a
Net Income (ttm) -290.03M
EPS (ttm) -1.16
PE Ratio (ttm) -1.98
Forward PE -3.45
Analyst Buy
Ask 2.32
Volume 10,048,004
Avg. Volume (20D) 7,431,806
Open 2.82
Previous Close 2.77
Day's Range 2.13 - 2.85
52-Week Range 1.52 - 10.50
Beta 1.64

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 328
Stock Exchange NASDAQ
Ticker Symbol SANA
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for SANA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 292.16% from the latest price.

Stock Forecasts
1 day ago
-17.69%
Sana Biotechnology shares are trading lower. The c... Unlock content with Pro Subscription
2 months ago
+160.61%
Sana Biotechnology shares are trading higher after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.